News 
Market Data 
Discover
Replies to post #327894 on Avid Bioservices Inc (CDMO)
John Stafford ties with Xencor is the puzzling part
Ronin wants to Halt PS Targeting and concentrate on Avid
John Stafford leaves BOD of Xencor and why?
...
...
Xencor and Merck have some agreements....John Stafford leaves Xencor....i wonder if he needed some distance??
Xencor Licenses Fc Antibody Engineering IP to Merck
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133277372
....
....
..and antibodies by design .... or "Imagine if you had molecules that had the kind of activity profile of a Blincyto but didn’t have the acute toxicity, that didn’t have the need for an infusion pump,"
http://www.xencor.com/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130719955
....
....
beta bodies patents...
1. A construct comprising an antibody Fc region operatively attached to two .beta.2-glycoprotein I (.beta.2GPI) polypeptides, wherein said .beta.2GPI polypeptides each comprise at least an intact domain V of .beta.2GPI, wherein said intact domain V binds to phosphatidylserine, wherein said .beta.2GPI polypeptides form a dimer when attached to said antibody Fc region and wherein said construct retains the property of binding to phosphatidylserine.
[0015] ReceptorBodies & BetaBodies: The invention first provides a range of phosphatidylserine binding construct compositions, in which the constructs comprise at least a first phosphatidylserine binding protein, polypeptide or receptor operatively attached to at least a first antibody Fc region. Joining a phosphatidylserine binding protein, polypeptide or "receptor" to an "antibody" Fc region gives rise to the terms "receptorbody" and "receptorbodies", which are used herein to refer to the phosphatidylserine-binding Fc constructs of the invention.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110933809
...
...
I believe I have shown why we should question every motive of Ronin group and I can go on about their candidate indirect ties to CSM Fargo but just these links above re: beta bodies patent and FC domain bindings.....and Stafford was with Xencor 18 years and now leaves as he seems to pretend he is not aware of PS Targeting potential with betabodies / FC binding domains and Xencor with agreements with Merck?? And NCCN trial with Merck !
...
...
Bio, John Stafford III is a businessman with an impeccable reputation that first put 12M into Xencor in 1999 and followed it up with additional larger amounts through Zen Investments. During his 18 years as investor and on Xencor's board they did licensing agreements with Roche, BI, Amgen, Pfizer and many others. There are no bogie man connection with any of these companies.
...
...
I've always liked your wild puzzle pieces but feel in this case they are misdirected.
...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133323010
....
...
Read again slowly above and think of the TOXICITY, and how Dr Jedd Wolchok just stated PS Targeting removes off target TOXICITIES....and these PS Targeting activities want to be HALTED by Ronin group ??!!!!
My suggestion is Ronin group best amend their plans and in writing, not over the phone....but SEC FILING saying no halting and keep Dr Jedd Wolchok, MSK, NCCN trials and other currently nondisclosed trials all active
Read CJs post about Dr Jedd Wolchok and you all should conclude the same
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133245961
...
...
